Testing lerapolturev for adults whose glioblastoma has come back
Original title: Lerapolturev (PVSRIPO) in GBM
How far along is this research?
This is a trial that is enrolling or has been updated. It is not a finding yet.
This is a middle stage study in people, and it is still a test.
Status: Recruiting. It is looking for patients now. Talk to your care team about whether it fits you.
The trial team last updated this record on . Always check the trial page for the latest.
The short version
This study is testing a treatment called lerapolturev in adults whose glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary has returned.
Who this trial is for. This trial is for adults with glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary that has come back. It tests two doses of lerapolturev put into the area where tumor is left after surgery, followed later by repeated shots under the skin near the lymph nodes of the head and neck. It takes place at the Preston Robert Tisch Brain Tumor Center at Duke.
Where it stands. The trial is looking at how safe this treatment is and how well it works. It has not reported results. The answer is not in yet.
What this means, and what it doesn't
What it could mean: This is one more thing being studied for glioblastoma: The fastest-growing type of glioma (grade 4). Treatment usually starts soon after diagnosis: surgery first, then radiation and chemotherapy. See the glossary that has come back. Someone who thinks they might fit can ask their care team about it. The care team can explain what taking part would involve.
What it doesn't mean: This does not mean lerapolturev works. A trial is a test, not a proven treatment. Being in a trial is not a guarantee that it will help you. It is not a promise of a cure.
Source: ClinicalTrials.gov, July 20, 2026 · Read the original
This plain-language summary was written by AI and published automatically after passing our automatic safety checks. How we write.